Cargando…

Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?

BACKGROUND: The rapidly developed vaccines against the severe acute respiratory syndrome coronavirus 2 carry a risk of provoking side effects. This study aimed to evaluate current vaccination non-serious/serious side effects. METHODS: A multicenter electronic questionnaire via an online platform was...

Descripción completa

Detalles Bibliográficos
Autores principales: Houshmand, Behzad, Keyhan, Seied Omid, Fallahi, Hamid Reza, Ramezanzade, Shaqayeq, Sadeghi, Erfan, Yousefi, Parisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755981/
https://www.ncbi.nlm.nih.gov/pubmed/35025010
http://dx.doi.org/10.1186/s40902-021-00330-6
_version_ 1784632483781804032
author Houshmand, Behzad
Keyhan, Seied Omid
Fallahi, Hamid Reza
Ramezanzade, Shaqayeq
Sadeghi, Erfan
Yousefi, Parisa
author_facet Houshmand, Behzad
Keyhan, Seied Omid
Fallahi, Hamid Reza
Ramezanzade, Shaqayeq
Sadeghi, Erfan
Yousefi, Parisa
author_sort Houshmand, Behzad
collection PubMed
description BACKGROUND: The rapidly developed vaccines against the severe acute respiratory syndrome coronavirus 2 carry a risk of provoking side effects. This study aimed to evaluate current vaccination non-serious/serious side effects. METHODS: A multicenter electronic questionnaire via an online platform was conducted over a 1-week period among vaccinated dental staff and dental students inquiring whether they experienced vaccine-related side-effects after vaccine administration. RESULTS: A total of 1205 respondents with a mean age of 39 (SD: 12) were retained for the analyses. The following vaccines were reported; Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV (Sinopharm). The majority of respondents received ChAdOx1 nCoV-19 (51.1%) and Gam-COVID-Vac (37.6%). The symptoms most frequently reported after vaccination were fatigue (79%), local pain in the injection site (77.4%), malaise (73%), and body pain (71.1%). Enrollees reported more onset of reactions on 0–12 h (44.1%) and 12–24 h (29.0%) after vaccine administration (p value <0.001). In 75.7%, the side effects last for up to 3 days. Merely 5.5% of cases reported the presence of side effects after the first week. Individuals with a history of SARSCoV-2 and other infections (MERS, influenza, and EBV) were more likely to report a number of unserious systemic side effects. CONCLUSION: The commonly reported adverse events were in line with similar studies. We have concerns with the frequency of serious adverse effects. This work necessitates the need for further clinical assessments with larger sample sizes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40902-021-00330-6.
format Online
Article
Text
id pubmed-8755981
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-87559812022-01-13 Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)? Houshmand, Behzad Keyhan, Seied Omid Fallahi, Hamid Reza Ramezanzade, Shaqayeq Sadeghi, Erfan Yousefi, Parisa Maxillofac Plast Reconstr Surg Research BACKGROUND: The rapidly developed vaccines against the severe acute respiratory syndrome coronavirus 2 carry a risk of provoking side effects. This study aimed to evaluate current vaccination non-serious/serious side effects. METHODS: A multicenter electronic questionnaire via an online platform was conducted over a 1-week period among vaccinated dental staff and dental students inquiring whether they experienced vaccine-related side-effects after vaccine administration. RESULTS: A total of 1205 respondents with a mean age of 39 (SD: 12) were retained for the analyses. The following vaccines were reported; Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV (Sinopharm). The majority of respondents received ChAdOx1 nCoV-19 (51.1%) and Gam-COVID-Vac (37.6%). The symptoms most frequently reported after vaccination were fatigue (79%), local pain in the injection site (77.4%), malaise (73%), and body pain (71.1%). Enrollees reported more onset of reactions on 0–12 h (44.1%) and 12–24 h (29.0%) after vaccine administration (p value <0.001). In 75.7%, the side effects last for up to 3 days. Merely 5.5% of cases reported the presence of side effects after the first week. Individuals with a history of SARSCoV-2 and other infections (MERS, influenza, and EBV) were more likely to report a number of unserious systemic side effects. CONCLUSION: The commonly reported adverse events were in line with similar studies. We have concerns with the frequency of serious adverse effects. This work necessitates the need for further clinical assessments with larger sample sizes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40902-021-00330-6. Springer Singapore 2022-01-13 /pmc/articles/PMC8755981/ /pubmed/35025010 http://dx.doi.org/10.1186/s40902-021-00330-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Houshmand, Behzad
Keyhan, Seied Omid
Fallahi, Hamid Reza
Ramezanzade, Shaqayeq
Sadeghi, Erfan
Yousefi, Parisa
Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title_full Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title_fullStr Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title_full_unstemmed Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title_short Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
title_sort vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in sars cov ii, gam-covid-vac (sputnik v), chadox1 ncov-19 (astrazeneca), bbv152 (covaxin), or bbibp-corv(sinopharm)?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755981/
https://www.ncbi.nlm.nih.gov/pubmed/35025010
http://dx.doi.org/10.1186/s40902-021-00330-6
work_keys_str_mv AT houshmandbehzad vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm
AT keyhanseiedomid vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm
AT fallahihamidreza vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm
AT ramezanzadeshaqayeq vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm
AT sadeghierfan vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm
AT yousefiparisa vaccineassociatedcomplicationsacomparativemulticenterevaluationamongdentalpractitionersanddentalstudentswhichcandidatevaccineismoresafeinsarscoviigamcovidvacsputnikvchadox1ncov19astrazenecabbv152covaxinorbbibpcorvsinopharm